GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620) clinical trials

TARSARC : TARGETING ATR IN SOFT-TISSUE SARCOMAS: A RANDOMIZED PHASE II STUDY

This study looks at a new drug, berzosertib, combined with standard gemcitabine chemotherapy, for adults with a type of soft-tissue cancer called leiomyosarcoma. It aims to see if the combination can better control the cancer's growth or shrink it, compared to gemcitabine alone.